PDCD1 and lymphopenia: Given that approximately 70% of lymphocytes in human blood are T cells, which are essential for anticancer immune responses, it is reasonable that systemic lymphopenia leading to TLP correlates with the efficacy of ICB therapies, such as anti-PD-1 (Supplementary Table S3).